Abstract
Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.